AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15901122 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise-based rehabilitation alone
Number of subjects: 34
Study 11997821 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 30
Study 11997821 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (PSS)
Number of subjects: 30
Study 9609266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestriol (3 mg per day)
Number of subjects: 72
Study 9609266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8730503 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2b‐IFN 3 M.U. thrice a week for six months (Group A)
Number of subjects: 36
Study 8730503 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2b‐IFN 3 M.U. thrice a week for 1 year (Group B)
Number of subjects: 36
Study 2226540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with APSAC
Number of subjects: 0
Study 2226540 — intervention group
Group type: COMPARATOR
Intervention: In-hospital thrombolysis
Number of subjects: 0
Study 2226540 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction
Number of subjects: 0
Study 2226540 — intervention group
Group type: COMPARATOR
Intervention: Total mortality
Number of subjects: 0
Study 755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-specific instructions plus feedback
Number of subjects: 60
Study 755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal suggestions plus feedback
Number of subjects: 60
Study 755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to rest plus feedback
Number of subjects: 60
Study 755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-specific instructions without feedback
Number of subjects: 60
Study 755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal suggestions without feedback
Number of subjects: 60
Study 755867 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to rest without feedback
Number of subjects: 60
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.1 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.35 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.5 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal adverse events with Oliceridine 0.1 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal adverse events with Oliceridine 0.35 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal adverse events with Oliceridine 0.5 mg
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 401
Study 31162798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.35 mg and 0.5 mg
Number of subjects: 401
Study 27917845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol (Group F)
Number of subjects: 80
Study 27917845 — intervention group
Group type: COMPARATOR
Intervention: Propofol and suxamethonium (Group S)
Number of subjects: 80
Study 25499648 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping application for 3 days
Number of subjects: 36
Study 25499648 — intervention group
Group type: COMPARATOR
Intervention: Inert Kinesio Taping application
Number of subjects: 36
Study 23271441 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 9497
Study 21521389 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily
Number of subjects: 34
Study 21521389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 84
Study 18645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 84
Study 16538534 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 600 mg daily for 2 weeks)
Number of subjects: 37
Study 16538534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 14641290 — intervention group
Group type: EXPERIMENTAL
Intervention: Heller's esophagomyotomy (H group)
Number of subjects: 20
Study 14641290 — intervention group
Group type: COMPARATOR
Intervention: Heller's esophagomyotomy with 360 degrees floppy Nissen fundoplication (H + N group)
Number of subjects: 20
Study 10914890 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan + pvm/ma + Zn + PPi
Number of subjects: 25
Study 10914890 — intervention group
Group type: COMPARATOR
Intervention: Triclosan + pvm/ma
Number of subjects: 25
Study 10914890 — intervention group
Group type: COMPARATOR
Intervention: Triclosan + Zn
Number of subjects: 25
Study 10914890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8855737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg and clarithromycin 250 mg (OC)
Number of subjects: 65
Study 8855737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 250 mg, and metronidazole 500 mg (OCM)
Number of subjects: 65
Study 1281043 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal radiation therapy by transcatheter hepatic arterial injection of [131I]‐Lp (group A)
Number of subjects: 27
Study 1281043 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy of Lp‐TAE (group B)
Number of subjects: 27
Study 6724847 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol Maleate (0.5%)
Number of subjects: 10
Study 6724847 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study 31193792 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention for gambling
Number of subjects: 321
Study 31193792 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 321
Study 29100645 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian/Axillary access (SCA)
Number of subjects: 202
Study 26796771 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment Questionnaire (WPAI)
Number of subjects: 70
Study 26796771 — intervention group
Group type: COMPARATOR
Intervention: Quality and Quantity questionnaire
Number of subjects: 70
Study 26796771 — intervention group
Group type: COMPARATOR
Intervention: WHO Health and Work Performance Questionnaire (HPQ)
Number of subjects: 70
Study 26796771 — intervention group
Group type: COMPARATOR
Intervention: Work Productivity Scale ‐ Rheumatoid Arthritis
Number of subjects: 70
Study 26796771 — intervention group
Group type: COMPARATOR
Intervention: Work Ability Index
Number of subjects: 70
Study 26796771 — intervention group
Group type: EXPERIMENTAL
Intervention: WPAI
Number of subjects: 70
Study 25662551 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete suture of the distal incision and relieving incision
Number of subjects: 40
Study 25662551 — intervention group
Group type: COMPARATOR
Intervention: Partial suture with only one suture knot for closure of the corner of the flap and closure of the distal incision, without suturing the relieving incision
Number of subjects: 40
Study 22920718 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50‐300 mg/day
Number of subjects: 149
Study 22920718 — intervention group
Group type: COMPARATOR
Intervention: Divalproex ER 500‐3000 mg/day
Number of subjects: 149
Study 22920718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 21498617 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost
Number of subjects: 24
Study 21498617 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 18224465 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized surgical technique for Nissen fundoplication
Number of subjects: 0
Study 18224465 — intervention group
Group type: COMPARATOR
Intervention: Standardized surgical technique
Number of subjects: 0
Study 17135807 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based version of the Four Word Delayed Recall Test
Number of subjects: 644
Study 17135807 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based version of the Four Word Delayed Recall Test
Number of subjects: 644
Study 17135807 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in Clinical Dementia Rating stage 0.5
Number of subjects: 644
Study 17135807 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with subjective memory complaints
Number of subjects: 644
Study 17135807 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with low education
Number of subjects: 644
Study 17135807 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial testing scores
Number of subjects: 644
Study 12955018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of growth hormone (GH) during puberty
Number of subjects: 0
Study 12955018 — intervention group
Group type: COMPARATOR
Intervention: Constant rate of growth hormone (GH) during puberty
Number of subjects: 0
Study 11089383 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 11089383 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 0
Study 9167371 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of 4% lidocaine spray
Number of subjects: 153
Study 9167371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) spray
Number of subjects: 153
Study 8141446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 30
Study 8141446 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 30
Study 3277569 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1, 2, 5, and 10 mg daily) plus atenolol
Number of subjects: 92
Study 3277569 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atenolol
Number of subjects: 92
Study 31586453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 52
Study 31586453 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 52
Study 27992260 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected Disturbance Program (UDP)
Number of subjects: 21
Study 27992260 — intervention group
Group type: EXPERIMENTAL
Intervention: UDP
Number of subjects: 21
Study 28440211 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 317
Study 28440211 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 317
Study 25511384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascophyllum nodosum (500 mg dried marine alga powder, ProDen PlaqueOff®)
Number of subjects: 61
Study 25511384 — intervention group
Group type: COMPARATOR
Intervention: Negative control tablets
Number of subjects: 61
Study 24726628 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-based definition of incident CKD stage 3
Number of subjects: 11560
Study 24726628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization-based definition of incident CKD stage 3
Number of subjects: 11560
Study 24726628 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization-based CKD diagnostic code
Number of subjects: 11560
Study 22623482 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2.5 mA, 15 min)
Number of subjects: 17
Study 22623482 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tsDCS (2.5 mA, 15 min)
Number of subjects: 17
Study 22623482 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS (2.5 mA, 15 min)
Number of subjects: 17
Study 20533573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-English speakers (Chinese and Spanish)
Number of subjects: 7023
Study 20533573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese speakers
Number of subjects: 7023
Study 20533573 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish speakers
Number of subjects: 7023
Study 20533573 — intervention group
Group type: COMPARATOR
Intervention: English speakers
Number of subjects: 7023
Study 18411235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure with heliox
Number of subjects: 12
Study 18411235 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen nasal continuous positive airway pressure
Number of subjects: 12
Study 15754137 — intervention group
Group type: EXPERIMENTAL
Intervention: Deciduous canine dentin
Number of subjects: 6
Study 15754137 — intervention group
Group type: EXPERIMENTAL
Intervention: MD sectioned deciduous canine dentin
Number of subjects: 6
Study 15754137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical area of MD sectioned deciduous canine dentin
Number of subjects: 6
Study 15754137 — intervention group
Group type: COMPARATOR
Intervention: Cervical area of BD sectioned premolar dentin
Number of subjects: 6
Study 12564617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamax I and II oxygen analysers
Number of subjects: 0
Study 12564617 — intervention group
Group type: COMPARATOR
Intervention: Douglas bag technique or Vmax 29 instrument (control methods)
Number of subjects: 0
Study 12564617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamax analysers
Number of subjects: 0
Study 12564617 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated values from raw data of Metamaxes
Number of subjects: 0
Study 19667499 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 0
Study 19667499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9368821 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 12 weeks plus regular dietary and behavioural support over two years
Number of subjects: 113
Study 9368821 — intervention group
Group type: COMPARATOR
Intervention: Supportive program only for two years
Number of subjects: 113
Study 1583392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (6 packets or 24 gm/day)
Number of subjects: 268
Study 1583392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 3709647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (8 mg)
Number of subjects: 0
Study 31295003 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant tumor group
Number of subjects: 246
Study 31295003 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 246
Study 29926300 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral PMTCT intervention
Number of subjects: 1398
Study 29926300 — intervention group
Group type: COMPARATOR
Intervention: Time-equivalent attention-control condition
Number of subjects: 1398
Study 26859381 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training Group (PTG)
Number of subjects: 20
Study 26859381 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study 24127266 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media recruitment (n = 138, 51.9%)
Number of subjects: 266
Study 24127266 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment methods (n = 125, 47.0%)
Number of subjects: 266
Study 23186026 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) - personalized advice added
Number of subjects: 150
Study 23186026 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention - assessment, feedback, and an informational leaflet
Number of subjects: 150
Study 20514787 — intervention group
Group type: EXPERIMENTAL
Intervention: Kligman's formula maintenance topical cream program (Group A)
Number of subjects: 30
Study 20514787 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional resurfacing using high power, fixed pulse width and low frequency (Group B)
Number of subjects: 30
Study 20514787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CO2 fractional resurfacing and Kligman's formula maintenance topical cream (Group C)
Number of subjects: 30
Study 18584251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool calgranulin B in colorectal cancer patients
Number of subjects: 152
Study 18584251 — intervention group
Group type: COMPARATOR
Intervention: Fecal occult blood test
Number of subjects: 152
Study 15921958 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 29
Study 15921958 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 29
Study 11818756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 80
Study 11818756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 10073600 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3-positive T cells
Number of subjects: 15
Study 10073600 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45RO-positive T cells
Number of subjects: 15
Study 10073600 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophages
Number of subjects: 15
Study 10073600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin
Number of subjects: 15
Study 10073600 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial-associated tissue factor
Number of subjects: 15
Study 10073600 — intervention group
Group type: COMPARATOR
Intervention: Control group (thin basement membrane disease)
Number of subjects: 15
Study 10073600 — intervention group
Group type: COMPARATOR
Intervention: Control group (humorally mediated glomerulonephritis)
Number of subjects: 15
Study 7734231 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment including hip and knee release, aponeurectomy of the iliotibial band, and z-shaped Achilles' tendon lengthening in group I (prophylactic treatment)
Number of subjects: 123
Study 7734231 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment including hip and knee release, aponeurectomy of the iliotibial band, and z-shaped Achilles' tendon lengthening in group II (treatment for existing contractures)
Number of subjects: 123
Study 7734231 — intervention group
Group type: COMPARATOR
Intervention: Natural history (control group of non-operated DMD patients)
Number of subjects: 123
Study 8123866 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer cells with high nuclear DNA content (specifically > 5C DNA content)
Number of subjects: 93
Study 8123866 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor (ER) negativity
Number of subjects: 93
Study 8123866 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of positive lymph nodes
Number of subjects: 93
Study 4006145 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal LAD occlusion
Number of subjects: 245
Study 4006145 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA occlusion
Number of subjects: 245
Study 4006145 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD occlusion
Number of subjects: 245
Study 4006145 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall occlusions
Number of subjects: 245
Study 4006145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperkinesis
Number of subjects: 245
Study 30977856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telephone use while driving (driving simulator test)
Number of subjects: 182
Study 30977856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telephone use while driving (compared to not using a mobile telephone)
Number of subjects: 182
Study 29733102 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone support
Number of subjects: 493
Study 29733102 — intervention group
Group type: COMPARATOR
Intervention: Reactive support
Number of subjects: 493
Study 27488888 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% inspiratory resistive breathing tasks (IRBT)
Number of subjects: 20
Study 27488888 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% inspiratory resistive breathing tasks (IRBT)
Number of subjects: 20
Study 25097285 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 25097285 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 0
Study 22822019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active spinal anesthesia with fentanyl (25 μg, intrathecal L(3)‐L(4))
Number of subjects: 8
Study 22822019 — intervention group
Group type: COMPARATOR
Intervention: Sham spinal anesthesia (NaCl, interspinous L(3)‐L(4))
Number of subjects: 8
Study 22822019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active spinal anesthesia with fentanyl
Number of subjects: 8
Study 20929127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Recipe (BSR)
Number of subjects: 35
Study 20929127 — intervention group
Group type: COMPARATOR
Intervention: alpha‐2b interferon
Number of subjects: 35
Study 17803698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone, 30 mg/day
Number of subjects: 30
Study 17803698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16142016 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg x 2/day)
Number of subjects: 14
Study 16142016 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg/day)
Number of subjects: 14
Study 12374719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation at removal (Group A)
Number of subjects: 126
Study 12374719 — intervention group
Group type: COMPARATOR
Intervention: Cuff deflation at removal (Group B)
Number of subjects: 126
Study 12374719 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison between Group A and Group B
Number of subjects: 126
Study 10628600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol, 0.35-0.60 g/kg body weight intravenously, during 1 hr, repeated daily during the first week postburn
Number of subjects: 17
Study 10628600 — intervention group
Group type: COMPARATOR
Intervention: Control subjects received the same amount of ethanol once
Number of subjects: 17
Study 7745515 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 957
Study 7745515 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 957
Study 2289995 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination (SD) medication, administered preoperatively
Number of subjects: 114